Overview
Gefticip contains Gefitinib 250 mg, a targeted therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of medications known as EGFR (epidermal growth factor receptor) inhibitors. By blocking EGFR, Gefticip helps stop the growth and spread of cancer cells that depend on this receptor for survival and proliferation.





